WEBSITE BSE:544502 NSE: AMANTA Inc. Year: 1994 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:54
No Notes Added Yet
Amanta Healthcare Ltd. is a pharmaceutical company based in Gujarat, India, specializing in manufacturing sterile liquid products, including intravenous (IV) fluids, injectables (large‑volume and small‑volume), ophthalmic solutions, respiratory care liquids, irrigation solutions, and related diluents. The company operates a WHO‑GMP and ISO‑certified manufacturing facility using advanced packaging technologies that allow production of sterile dosages in a wide range of container volumes. Amanta serves both domestic and international mar...Read More
Amanta Healthcare Ltd. is a pharmaceutical company based in Gujarat, India, specializing in manufacturing sterile liquid products, including intravenous (IV) fluids, injectables (large‑volume and small‑volume), ophthalmic solutions, respiratory care liquids, irrigation solutions, and related diluents. The company operates a WHO‑GMP and ISO‑certified manufacturing facility using advanced packaging technologies that allow production of sterile dosages in a wide range of container volumes. Amanta serves both domestic and international markets through a large distribution network and exports to multiple countries. In 2025, it raised capital through an IPO to expand production capacity, upgrade facilities, and support growth. Amanta Healthcare is positioned to benefit from rising demand for sterile injectables and IV fluids in India’s expanding healthcare sector, with success dependent on regulatory compliance, efficient capacity utilization, and stable raw-material supply. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹521 Cr.
Stock P/E 49.6
P/B 2.4
Current Price ₹134.2
Book Value ₹ 55.4
Face Value 10
52W High ₹154.9
Dividend Yield 0%
52W Low ₹ 93.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Net Sales | 68 | 67 | 68 | 65 | 71 | 74 |
| Other Income | 0 | 0 | 1 | 1 | 0 | 1 |
| Total Income | 68 | 67 | 69 | 66 | 71 | 75 |
| Total Expenditure | 55 | 53 | 53 | 50 | 56 | 59 |
| Operating Profit | 14 | 14 | 16 | 16 | 15 | 16 |
| Interest | 9 | 6 | 6 | 6 | 5 | 5 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -3 | 0 |
| Profit Before Tax | -1 | 3 | 6 | 5 | 2 | 6 |
| Provision for Tax | -0 | 1 | 1 | 1 | 1 | 2 |
| Profit After Tax | -0 | 2 | 4 | 4 | 1 | 5 |
| Adjustments | 0 | -0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | -0 | 2 | 4 | 4 | 1 | 5 |
| Adjusted Earnings Per Share | -0.1 | 0.8 | 1.5 | 1.2 | 0.4 | 1.3 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 175 | 203 | 211 | 192 | 185 | 184 | 171 | 225 | 259 | 280 | 275 | 278 |
| Other Income | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 5 | 1 | 1 | 3 |
| Total Income | 176 | 204 | 212 | 194 | 187 | 187 | 172 | 226 | 265 | 282 | 276 | 281 |
| Total Expenditure | 139 | 161 | 160 | 145 | 144 | 147 | 133 | 172 | 208 | 223 | 215 | 218 |
| Operating Profit | 37 | 43 | 52 | 49 | 43 | 40 | 39 | 54 | 56 | 59 | 61 | 63 |
| Interest | 12 | 14 | 12 | 20 | 41 | 38 | 40 | 44 | 35 | 34 | 28 | 22 |
| Depreciation | 12 | 14 | 15 | 16 | 17 | 16 | 17 | 17 | 18 | 20 | 18 | 20 |
| Exceptional Income / Expenses | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 69 | 0 | 0 | 0 | -3 |
| Profit Before Tax | 13 | 15 | 25 | 12 | -14 | -15 | -18 | 62 | 3 | 5 | 15 | 19 |
| Provision for Tax | 12 | 3 | 2 | 1 | 4 | 4 | 4 | 8 | 5 | 2 | 4 | 5 |
| Profit After Tax | 1 | 13 | 23 | 11 | -19 | -19 | -22 | 54 | -2 | 4 | 11 | 14 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 13 | 23 | 11 | -19 | -19 | -22 | 54 | -2 | 4 | 11 | 14 |
| Adjusted Earnings Per Share | 0.2 | 3.4 | 6.3 | 4.3 | -7 | -7 | -8.1 | 20.1 | -0.8 | 1.4 | 3.6 | 4.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -2% | 7% | 8% | 5% |
| Operating Profit CAGR | 3% | 4% | 9% | 5% |
| PAT CAGR | 175% | -41% | 0% | 27% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 13% | 5% | 9% | -0% |
| ROCE Average | 15% | 14% | 18% | 14% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 169 | 192 | 215 | 67 | 48 | 29 | 7 | 65 | 63 | 66 | 96 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 38 | 42 | 32 | 200 | 196 | 192 | 158 | 176 | 176 | 149 | 132 |
| Other Non-Current Liabilities | 33 | 37 | 40 | 49 | 74 | 93 | 104 | 27 | 38 | 35 | 42 |
| Total Current Liabilities | 99 | 97 | 102 | 90 | 85 | 73 | 123 | 112 | 97 | 105 | 118 |
| Total Liabilities | 338 | 369 | 390 | 406 | 403 | 388 | 392 | 379 | 374 | 355 | 389 |
| Fixed Assets | 235 | 246 | 262 | 267 | 247 | 244 | 242 | 241 | 238 | 228 | 217 |
| Other Non-Current Assets | 14 | 28 | 26 | 33 | 41 | 39 | 20 | 6 | 5 | 6 | 31 |
| Total Current Assets | 90 | 95 | 102 | 107 | 115 | 105 | 131 | 133 | 131 | 121 | 141 |
| Total Assets | 338 | 369 | 390 | 406 | 403 | 388 | 392 | 379 | 374 | 355 | 389 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 0 | 3 | 9 | 1 | 0 | 6 | 0 | 2 |
| Cash Flow from Operating Activities | 25 | 40 | 40 | 25 | 32 | 38 | 33 | 64 | 43 | 58 | 47 |
| Cash Flow from Investing Activities | -37 | -36 | -21 | -175 | -5 | -11 | -17 | -5 | -7 | -10 | -24 |
| Cash Flow from Financing Activities | 11 | -3 | -20 | 152 | -21 | -35 | -17 | -52 | -42 | -46 | -23 |
| Net Cash Inflow / Outflow | -0 | 0 | -0 | 2 | 6 | -8 | -0 | 6 | -6 | 1 | -1 |
| Closing Cash & Cash Equivalent | 1 | 1 | 0 | 3 | 9 | 1 | 1 | 6 | 0 | 2 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.15 | 3.44 | 6.3 | 4.26 | -6.99 | -7.04 | -8.14 | 20.08 | -0.79 | 1.35 | 3.64 |
| CEPS(Rs) | 3.58 | 7.18 | 10.27 | 10.43 | -0.82 | -0.89 | -1.79 | 26.52 | 6.05 | 8.71 | 10.02 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 34.05 | 40.02 | 46.32 | 24.98 | 17.88 | 10.85 | 2.71 | 24.22 | 23.44 | 24.71 | 33.43 |
| Core EBITDA Margin(%) | 19.08 | 19.22 | 22.8 | 23.91 | 22.13 | 20.27 | 22.38 | 23.79 | 19.64 | 20.51 | 21.72 |
| EBIT Margin(%) | 13.16 | 13.57 | 16.61 | 16.61 | 14.1 | 12.48 | 13.06 | 46.89 | 14.65 | 13.92 | 15.53 |
| Pre Tax Margin(%) | 6.8 | 7.08 | 11.15 | 6.39 | -7.84 | -8.2 | -10.37 | 27.41 | 1.04 | 1.92 | 5.35 |
| PAT Margin (%) | 0.29 | 5.88 | 10.3 | 5.84 | -10.14 | -10.24 | -12.75 | 23.9 | -0.81 | 1.3 | 3.82 |
| Cash Profit Margin (%) | 6.95 | 12.28 | 16.8 | 14.32 | -1.19 | -1.29 | -2.81 | 31.56 | 6.27 | 8.33 | 10.52 |
| ROA(%) | 0.17 | 3.57 | 6.1 | 2.85 | -4.64 | -4.78 | -5.6 | 13.97 | -0.56 | 1 | 2.82 |
| ROE(%) | 0.44 | 9.33 | 14.59 | 9.57 | -32.75 | -48.98 | -120.09 | 149.18 | -3.3 | 5.63 | 12.91 |
| ROCE(%) | 9.83 | 10.63 | 12.69 | 10.33 | 8.44 | 8.27 | 8.91 | 39.99 | 13.43 | 14.19 | 15.16 |
| Receivable days | 71.51 | 78.91 | 91.57 | 108.35 | 104.95 | 103.45 | 110.55 | 77.95 | 69.3 | 66.24 | 65.27 |
| Inventory Days | 64.67 | 56.98 | 48.15 | 59.15 | 71.29 | 76.92 | 102.89 | 103.89 | 98.61 | 83.57 | 87.98 |
| Payable days | 150.89 | 132.35 | 150.3 | 170.71 | 139.77 | 112.43 | 157.26 | 290.83 | 223.28 | 158.77 | 175.62 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.97 | 0.84 | 0.78 | 1.43 | 1.42 | 1.37 | 1.47 | 1.06 | 0.92 | 0.81 | 0.8 |
| EV/Core EBITDA(x) | 4.57 | 3.96 | 3.14 | 5.64 | 6.16 | 6.37 | 6.41 | 4.39 | 4.24 | 3.88 | 3.61 |
| Net Sales Growth(%) | 5.89 | 15.92 | 4.15 | -9.29 | -3.49 | -0.27 | -7.09 | 31.61 | 14.94 | 8.19 | -2.01 |
| EBIT Growth(%) | -25.66 | 18.52 | 28 | -13.77 | -19.09 | -11.7 | -2.75 | 372.38 | -64.09 | 2.81 | 9.3 |
| PAT Growth(%) | -96.38 | 2198.89 | 83.3 | -51.06 | -265.41 | -0.69 | -15.68 | 346.78 | -103.92 | 272.14 | 189.02 |
| EPS Growth(%) | -96.38 | 2169.67 | 83.3 | -32.41 | -264.16 | -0.69 | -15.68 | 346.78 | -103.92 | 272.14 | 168.97 |
| Debt/Equity(x) | 0.56 | 0.49 | 0.4 | 3.83 | 5.18 | 7.94 | 32.3 | 3.41 | 3.43 | 3.1 | 2.02 |
| Current Ratio(x) | 0.91 | 0.97 | 1 | 1.18 | 1.35 | 1.43 | 1.06 | 1.19 | 1.35 | 1.15 | 1.19 |
| Quick Ratio(x) | 0.54 | 0.66 | 0.71 | 0.81 | 0.9 | 0.9 | 0.6 | 0.55 | 0.64 | 0.59 | 0.57 |
| Interest Cover(x) | 2.07 | 2.09 | 3.04 | 1.63 | 0.64 | 0.6 | 0.56 | 2.41 | 1.08 | 1.16 | 1.53 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 63.56 | 63.56 | 63.56 | 63.72 |
| FII | 2.21 | 1 | 1.1 | 0.85 |
| DII | 10.72 | 11.34 | 11.24 | 12.88 |
| Public | 23.52 | 24.1 | 24.1 | 22.56 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 2.47 | 2.47 | 2.47 | 2.47 |
| FII | 0.09 | 0.04 | 0.04 | 0.03 |
| DII | 0.42 | 0.44 | 0.44 | 0.5 |
| Public | 0.91 | 0.94 | 0.94 | 0.88 |
| Others | 0 | 0 | 0 | 0 |
| Total | 3.88 | 3.88 | 3.88 | 3.88 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
